April 2, 2012
Toray Industries and Taiho Pharmaceutical announced on March 30 that the two companies had reached an agreement to terminate the co-development of β3-adrenoceptor agonist TRK-380 (development code for Toray) or TAC-301 (for Taiho), which the two companies have been developing...read more